Oruka Therapeutics to Present at Multiple March Investor Conferences

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

TD Cowen’s 45^th Annual Health Care Conference

Date: Tuesday, March 4^th, 2025

Time: 10:30AM ET

Leerink Global Healthcare Conference

Date: Wednesday, March 12^th, 2025

Time: 8:40AM ET

A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at .

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.

Investor Contact: 

Alan Lada 

(650)-606-7911